Abstract 28P
Background
Obesity and related diseases, namely, diabetes and metabolic syndrome, are associated with chronic inflammation and colorectal cancer (CRC). In CRC liver metastases (mCRC) and adjacent liver tissue defects are formed in the mitochondrial electron transport chain that causes mitochondrial dysfunction, activation of redox-molecules (SR, NO) generation sources and MMP-2, -9 activity. Radical oxygen species take a part in the regulation of gelatinases (MMP-2 and -9) and the xanthine/xanthine oxidase reaction is widely used as a source of exogenous ROS in considering of MMPs. The aim of the study was to determine the state of XO, SR and MMPs in liver tissue and CRC liver metastases (MT) and set the clinical significance of obtained results.
Methods
The prospective study on 37 mCRC patients who underwent the liver resection due metastatic disease has been performed. The rate of SR generation of neutrophils and in the tissue samples, the rate of XO and the activity of matrix metalloproteinases in the tissue samples was measured accordingly study design.
Results
The highest level of XO in mCRC patients was detected in metastatic tissue (1.47±0.18 a.u.). The level of XO enzyme in the adjacent tissue (AT) and distant tissue (DT) were 0.38±0.10 a.u. (p<0.05) and 0.19±0.008 a.u. (р<0,05) respectively. A correlation was found between the BMI and amount of XO in DT of the liver r2 = 0,64. The total activity of gelatinases in subgroup of mCRC patients with BMI ≥ 25 was found to be significantly higher than in normal body weight patients withing the DT (1.52; p<0.001), as well as in the AT (1.28 times; p<0.001). High XO levels (HR (95% CI) = 0,002 (2,63 to 15.05) P = 0,002) and SR generation levels (HR (95% CI) = 0,01 (2,4 to 10,37) P = 0,01) in adjusted liver tissue to metastatic lesions had a negative impact on overall overall survival rates.
Conclusions
Xanthine oxidase and superoxide radicals can be a new metastatic disease prognostic factors for colorectal cancer patients, the latter requiring further randomized trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09